| pubmed-article:8584610 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C0031268 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C0023688 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C1623287 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C2827063 | lld:lifeskim |
| pubmed-article:8584610 | lifeskim:mentions | umls-concept:C0074160 | lld:lifeskim |
| pubmed-article:8584610 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8584610 | pubmed:dateCreated | 1996-3-19 | lld:pubmed |
| pubmed-article:8584610 | pubmed:abstractText | SCH 39166 is the first selective D1-dopamine receptor antagonist developed for clinical trials in schizophrenia. SCH 39166 was evaluated as a radioligand for PET, labeled with 11C, and as a D1-dopamine receptor antagonist after single oral doses in healthy men. After intravenous injection of [11C]SCH 39166 distribution of radioactivity in brain grossly reflected D1-dopamine receptor density. The putamen to cerebellum ratio at equilibrium was low (1.54 +/- 0.18 SD), which makes [11C]SCH 39166 less suitable as a radioligand for applied PET studies. Saturability of specific binding was demonstrated after IV injection of [11C]SCH 39166 with low specific radioactivity. Stereospecificity of binding was examined using the stereoisomer [11C]SCH 39165. D1-Receptor occupancy was demonstrated with [11C]SCH 39166 2 h after administration of single oral doses of unlabeled SCH 39166 to each of three healthy subjects (25, 100 and 400 mg). There was a substantial reduction of specific [11C]SCH 39166 uptake in the putamen after all doses. Single oral doses of 100 mg induced approximately 70% D1-dopamine receptor occupancy in the basal ganglia, which should be sufficient to investigate the antipsychotic potential of D1-dopamine receptor antagonism in clinical studies. | lld:pubmed |
| pubmed-article:8584610 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8584610 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8584610 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8584610 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8584610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8584610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8584610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8584610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8584610 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8584610 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:8584610 | pubmed:issn | 0033-3158 | lld:pubmed |
| pubmed-article:8584610 | pubmed:author | pubmed-author:SedvallGG | lld:pubmed |
| pubmed-article:8584610 | pubmed:author | pubmed-author:SwahnC GCG | lld:pubmed |
| pubmed-article:8584610 | pubmed:author | pubmed-author:FardeLL | lld:pubmed |
| pubmed-article:8584610 | pubmed:author | pubmed-author:HalldinCC | lld:pubmed |
| pubmed-article:8584610 | pubmed:author | pubmed-author:KarlssonPP | lld:pubmed |
| pubmed-article:8584610 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8584610 | pubmed:volume | 121 | lld:pubmed |
| pubmed-article:8584610 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8584610 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8584610 | pubmed:pagination | 300-8 | lld:pubmed |
| pubmed-article:8584610 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:meshHeading | pubmed-meshheading:8584610-... | lld:pubmed |
| pubmed-article:8584610 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8584610 | pubmed:articleTitle | Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man. | lld:pubmed |
| pubmed-article:8584610 | pubmed:affiliation | Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:8584610 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8584610 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8584610 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8584610 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
